BWVI Blue Water Ventures International

A Portion of Pulaski Shipwreck Coin Collection Has Sold

A Portion of Pulaski Shipwreck Coin Collection Has Sold

St Petersburg, FL, Feb. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Endurance Exploration Group (OTC: EXPL) and expedition partner, Blue Water Ventures International (OTCPK: BWVI), are pleased to announce that they have sold a portion of the rare coins recovered from the SB Pulaski wreck site during the 2018 dive season. The joint venture partners have retained certain coins, as well as unique and valuable artifacts for monetization at a later date, and will provide the opportunity for display, academic study, and public viewing.

The proceeds from the sale of these coins was sufficient to recoup the costs of salvage efforts in 2018 and will provide sufficient working capital for the upcoming 2019 salvage season. The coin sales will allow the expedition partners to continue excavating the 1838 SB Pulaski wreck site, which is estimated to still contain 98% of its coins, precious metals, and additional valuable artifacts. The JV Partners estimate that they have only recovered approximately 2% of the valuable cargo from the shipwreck and are eager to commence the 2019 dive season and continue the potentially lucrative salvage effort.

Further, the proceeds from the coin sales will provide additional working capital to commence salvage operations on additional wreck sites, such as the recently arrested 1840 loss of steamship, ‘North Carolina’, which was once owned by the Vanderbilt shipping line.

Selected coins were sold to one of the world’s largest coin distribution companies, Asset Marketing Services (AMS) who is making selected coins available to their numismatic collecting clients.   Collectors interested in acquiring coins from the Pulaksi shipwreck may contact AMS at Govmint.com.

AMS CEO, Bill Gale, commented, “At the time the SS Pulaski sailed, Americans carried both foreign and U.S. coins in their pockets and they made no distinction between the two in daily commerce. This changed in 1857, when foreign coins were no longer considered U.S. legal tender, but the Pulaski treasure offers a fascinating glimpse into how Americans viewed their money during our first 80 years as a country. Another thing that impressed me was the high quality of the U.S. coins recovered from the wreck. Even though the coins were lost at sea over 180 years ago, many of the recovered coins are in astonishingly good condition.” 

Blue Water Ventures CEO, Keith Webb, commented, “To see these coins come to life after almost 200 years underwater, is a site to behold.  We are thrilled that Asset Marketing Services will be able to share these special coins with the public.”

About Asset Marketing Services, Inc:

Since 1984 Asset Marketing Services (AMS) has provided collectors, history buffs and others with ancient coins that date back more than 2,000 years to the latest three-dimensional works of modern coin art and everything in between.  Asset Marketing Services® / AMS® is a private distributor of coin and currency issues and privately licensed collectibles, and is not affiliated with the U.S. government. ModernCoinMart®, MCM® and ® are brands of AMS

About Endurance Exploration Group, Inc.:

Endurance Exploration Group, Inc. specializes in historic shipwreck research, subsea search, survey and recovery of lost ship containing valuable cargoes. Over the last 5 years, Endurance has developed a research database of over 1,400 ships that are known to be lost with valuable cargoes in the world oceans. For more information go to .

About Blue Water Ventures International, Inc.:

The Company is engaged in the business of conducting archaeologically-sensitive recoveries of cargo and artifacts from shipwrecks. Its operations to date have focused on shallow water search and recovery projects in less than 150 feet of water. The Company is now expanding its focus to include deep-water salvage of historic and modern-day shipwrecks. For more information go to 

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to certain risks and uncertainties including, but not limited to: ability to further strengthen our balance sheet, ability to raise funding for continued operations, ability to successfully and profitably locate additional wrecks and cargo, ability to establish ownership, and other factors. Therefore, actual results may differ materially from those indicated or implied by such forward-looking statements. Except as required by law, the Company disclaims any obligation to publicly update such statements.



Contact:

Endurance Exploration Group, Inc.
Micah Eldred
727-533-5555
     

Blue Water Ventures International, Inc.
Keith Webb
904-215-7601
 
EN
13/02/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Water Ventures International

 PRESS RELEASE

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick...

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, hosted Rick Doblin, the Founder and Preside...

 PRESS RELEASE

Psycheceutical Bioscience, Inc. Announces Observational Research Resul...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical creamPatients indicated their thought processes were clearer and more focused, and were more keenly aware of surroundings MIAMI, March 21, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge tec...

 PRESS RELEASE

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trial...

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in AustraliaPhase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect™ ketaminePhase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirect™ ketamine on improving their symptoms MIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- (OTCPK: BWVI) ("Psycheceutical"...

 PRESS RELEASE

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for To...

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (F...

 PRESS RELEASE

Psycheceutical Bioscience Provisional Patent Application for Novel Ket...

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD) MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD). The...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch